David Y. Graham, MD; Ginger M. Lew, PA-C; Dolores G. Evans, PhD; Doyle J. Evans Jr., PhD; Peter D. Klein, PhD
▪ Objective: To determine whether antimicrobial therapy for Helicobacter pylori infection accelerates the healing of duodenal ulcers.
▪ Design: Single-blind, randomized, controlled trial.
▪ Setting: Veterans Affairs hospital.
▪ Participants: One hundred and five patients with endoscopically verified duodenal ulcers.
▪ Intervention: Patients received either ranitidine, 300 mg/d, or ranitidine, 300 mg/d, plus "triple therapy" (2 g/d of tetracycline, 750 mg/d of metronidazole, and 5 or 8 bismuth subsalicylate tablets per day). Triple therapy was administered for only the first 2 weeks of ulcer treatment.
▪ Measurements: Videoendoscopic assessment of ulcer status was done until ulcer healing was complete. Evaluations were done after 2, 4, 8, 12, and 16 weeks of therapy.
▪ Main Results: Ulcer healing was more rapid in patients receiving ranitidine plus triple therapy than in patients receiving ranitidine alone (P < 0. 01). The cumulative percentages of patients with healed ulcers in the group receiving ranitidine plus triple therapy and in the group receiving ranitidine alone were as follows: 37% and 18% after week 2; 74% and 53% after week 4; 84% and 68% after week 8; 96% and 80% after week 12; and 98% and 84% after week 16.
▪ Conclusion: Combined therapy with anti-H. pylori agents and ranitidine was superior to ranitidine alone for duodenal ulcer healing. Our results indicate that H. pylori plays a role in duodenal ulcer disease.
Graham DY, Lew GM, Evans DG, Evans DJ, Klein PD. Effect of Triple Therapy (Antibiotics plus Bismuth) on Duodenal Ulcer Healing: A Randomized Controlled Trial. Ann Intern Med. 1991;115:266–269. doi: 10.7326/0003-4819-115-4-266
Download citation file:
Published: Ann Intern Med. 1991;115(4):266-269.
Gastroenterology/Hepatology, Peptic Disease, Peptic Ulcer.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use